Immunoglobulin and biologic industry leaders gather to advance immunoglobulin therapy and biologics.
LAS VEGAS, Oct. 15, 2026 /PRNewswire-PRWeb/ — This week, Immunoglobulin National Society (IgNS) is convening its 15th National Conference, bringing more than 1,500 attendees from over 500 companies to Red Rock Casino Resort & Spa, Oct. 15–18, for four days of education, collaboration, and networking focused on advancing Ig and biologics.
This year’s program features more than 50 clinical and business sessions and offers more than 30 continuing education (CE/CME) and recertification units, addressing the clinical, operational, business, and regulatory issues shaping the field as new therapies and indications emerge, sites of care evolve, and industry challenges continue to grow.
Program highlights include:
- Seminars and specialized educational tracks for clinical, operational, and business leaders
- Practice-focused programming addressing key issues shaping care delivery, business operations, and the regulatory landscape
- Networking opportunities to build professional connections and encourage collaboration
- Expo Hall featuring leading companies and industry partners offering therapies, resources, services, and solutions
“Celebrating our 15th National Conference is an exciting milestone for IgNS,” said Luba Sobolevsky, PharmD, IgCP®, President and CEO of IgNS. “We have grown alongside an industry that continues to expand in scope and complexity. This year, we celebrate that progress and look ahead, bringing leaders from across the Ig and biologics industry together to address shared challenges, advance clinical and operational excellence, and help shape the future of the field.”
“Fifteen years ago, this conference was created around the recognition that immunoglobulin therapy requires specialized knowledge, education, and collaboration,” said Amy Clarke, DNP, RN, IgCN®, Chief Clinical Officer of IgNS. “Today, that mission is more important than ever. As new therapies and indications emerge and care expands across settings, we have an opportunity and a responsibility to ensure that clinical practice evolves with the science and that patients receive safe, high-quality care wherever they are treated.”
For conference information, including program details and registration, visit: conferences.ig-ns.org/event/IgNS-2026.
About the Immunoglobulin National Society (IgNS)
The Immunoglobulin National Society (IgNS) is the leading national organization dedicated to advancing immunoglobulin therapy and biologics across all sites of care. Representing more than 40,000 healthcare and industry professionals and 9,000 patients, IgNS delivers evidence-based standards and guidelines, specialized education, professional credentialing, and essential resources to advance clinical care, operational excellence, and patient outcomes. Through collaboration with leading clinicians and industry stakeholders, IgNS advances research, advocacy, innovation, and interdisciplinary expertise across the Ig and biologics industry. For more information, visit ig-ns.org.
Media Contact
Jacqueline O’Dell
Immunoglobulin National Society
888.855.4443
info@ig-ns.org